Autoantibodies to ADAMTS13 in human immunodeficiency virus-associated thrombotic thrombocytopenic purpura

被引:0
|
作者
Meiring, Muriel [1 ,2 ]
Khemisi, Mmakgabu [1 ,2 ]
Louw, Susan [2 ,3 ]
Krishnan, Palanisamy [1 ]
机构
[1] Univ Free State, Fac Hlth Sci, Dept Haematol & Cell Biol, Bloemfontein, South Africa
[2] Univ Business Unit, Natl Hlth Lab Serv, Bloemfontein, South Africa
[3] Univ Witwatersrand, Dept Mol Med & Haematol, Johannesburg, South Africa
基金
新加坡国家研究基金会;
关键词
ADAMTS13; autoantibodies; HIV; thrombotic thrombocytopenic purpura; ANTI-ADAMTS13; ANTIBODIES; PLASMA-EXCHANGE; SPACER DOMAIN; HIV; INFECTION; IGG; INFUSION; CLEAVAGE; BINDING;
D O I
10.1111/vox.13738
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and Objectives: Thrombotic thrombocytopenic purpura (TTP) is a potentially fatal thrombotic microangiopathic disorder that can result from human immunodeficiency virus (HIV) infection. The pathogenesis involves a deficiency of the von Willebrand factor (vWF) cleaving protease ADAMTS13 (a disintegrin and metalloprotease with thrombospondin motifs member 13) and the presence of antiADAMTS13 autoantibodies. However, there is insufficient information regarding the epitope specificity and reactivity of these autoantibodies. This study aimed to perform epitope-mapping analysis to provide novel insights into the specific epitopes on ADAMTS13 domains affected by autoantibodies. Materials and Methods: The study analysed 59 frozen citrate plasma samples from HIV-associated TTP patients in South Africa, measuring ADAMTS13 activity using Technozyme (R) (R) ADAMTS13 activity test, total immunoglobulin (Ig) M and IgA antibodies levels using ELISA kit and purifying IgG antibodies using NAbTM Protein G spin columns. A synthetic ADAMTS13 peptide library was used for epitope mapping. Results: Overall, 90% of samples showed anti-ADAMTS13 IgG autoantibodies, with 64% of these antibodies being inhibitory, as revealed by mixing studies. Samples with ADAMTS13 antigen levels below 5% showed high anti-ADAMTS13 IgG autoantibody titres (>= 50 IU/mL), whereas those with 5%-10% levels had low autoantibody titres (<50 IU/mL).The metalloprotease, cysteine-rich and spacer domains were 100% involved in binding anti-ADAMTS13 IgG antibodies, with 58% of samples containing antibodies binding to the C-terminal part of the ADAMTS13 disintegrin-like domain, indicating different pathogenic mechanisms. Conclusion: The metalloprotease, cysteine-rich and spacer domains are the primary targets for anti-ADAMTS13 IgG autoantibodies in patients with HIV-associated TTP. These findings suggest potential effects on the proteolytic activity of ADAMTS13, highlighting the complex nature of the pathogenic mechanisms involved.
引用
收藏
页码:1285 / 1294
页数:10
相关论文
共 50 条
  • [31] Pathogenesis of thrombotic thrombocytopenic purpura: ADAMTS13 deficiency and beyond
    Lian, ECY
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2005, 31 (06): : 625 - 632
  • [32] Identification of ADAMTS13 Peptide Sequences Recognized by Autoantibodies in Patients with Acquired Thrombotic Thrombocytopenic Purpura
    Yamaguchi, Yusuke
    Moriki, Takanori
    Wada, Hideo
    Matsumoto, Masanori
    Fujimura, Yoshihiro
    Nakagawa, Terumichi
    Igari, Atsuko
    Ikeda, Yasuo
    Murata, Mitsuru
    BLOOD, 2008, 112 (11) : 797 - 798
  • [33] Diagnosis of Thrombotic Thrombocytopenic Purpura by ADAMTS13 Activity Quantification
    Dimopoulos, Konstantinos
    Philips, Malou
    Goetze, Jens P.
    JOURNAL OF APPLIED LABORATORY MEDICINE, 2022, 7 (03): : 637 - 649
  • [34] Utility of ADAMTS13 Assays in Diagnosing Thrombotic Thrombocytopenic Purpura
    Lehman, Christopher M.
    Rodgers, George M.
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2015, 139 (04) : 433 - 433
  • [35] Molecular basis of ADAMTS13 dysfunction in thrombotic thrombocytopenic purpura
    Minola Manea
    Diana Karpman
    Pediatric Nephrology, 2009, 24 : 447 - 458
  • [36] Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura
    Sadler, J. Evan
    BLOOD, 2008, 112 (01) : 11 - 18
  • [37] ADAMTS13 Biomarkers in Management of Immune Thrombotic Thrombocytopenic Purpura
    Sui, Jingrui
    Zheng, Liang
    Zheng, X. Long
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2023, 147 (08) : 974 - 979
  • [38] Advantages and limits of ADAMTS13 testing in thrombotic thrombocytopenic purpura
    Franchini, Massimo
    Mannucci, Pier Mannuccio
    BLOOD TRANSFUSION, 2008, 6 (03) : 127 - 135
  • [39] Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura
    Han-Mou Tsai
    Journal of Molecular Medicine, 2002, 80 : 639 - 647
  • [40] ADAMTS13 Mutations and Polymorphisms in Congenital Thrombotic Thrombocytopenic Purpura
    Lotta, Luca A.
    Garagiola, Isabella
    Palla, Roberta
    Cairo, Andrea
    Peyvandi, Flora
    HUMAN MUTATION, 2010, 31 (01) : 11 - 19